戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tion mediated by esophagus-enriched peptidyl arginine deiminases.
2  CHD4 regulates expression of PADI1 (Protein Arginine Deiminase 1) and PADI3 in multiple cancer cell
3  (and novel) interacting partners of protein arginine deiminase 2 (PAD2) and pyruvate dehydrogenase k
4                                      Protein arginine deiminase 2 (PAD2) plays a key role in the onse
5                                     Peptidyl arginine deiminase 2 (PAD2), an enzyme that converts pro
6 and its conversion to citrulline by peptidyl arginine deiminase 2 (PADI2), an enzyme that has been as
7 with live neutrophils or recombinant protein arginine deiminases 2 or 4 at 37 degrees C resulted in i
8                                     Peptidyl arginine deiminase-2 and cyclic nucleotide phosphodieste
9 lular domain of LRP1 is a target of peptidyl arginine deiminase-2-mediated deimination in vitro.
10  CCCA, only 1 gene (PADI3, encoding peptidyl arginine deiminase 3) has been thus far associated with
11 e identified citrullination sites in protein arginine deiminase 4 (12 sites) and in fibrinogen (25 si
12 ) to citrulline with recombinant polypeptide arginine deiminase 4 (PAD4) abolished ADAMDEC1-catalyzed
13  events in NET formation, including peptidyl arginine deiminase 4 (PAD4) activity, neutrophil nuclear
14           Unlocking the potential of protein arginine deiminase 4 (PAD4) as a drug target for rheumat
15                                      Protein arginine deiminase 4 (PAD4) facilitates the post-transla
16 and functional experiments implicate protein arginine deiminase 4 (PAD4) in the pathogenesis of rheum
17   The presumed role of an overactive protein arginine deiminase 4 (PAD4) in the pathophysiology of rh
18 and the immunotherapeutic synergy of protein arginine deiminase 4 (PAD4) inhibitors, which curtail NE
19                                      Protein arginine deiminase 4 (PAD4) is a Ca(2+)-dependent enzyme
20                                      Protein arginine deiminase 4 (PAD4) is a transcriptional coregul
21       Citrullination of histones by peptidyl arginine deiminase 4 (PAD4) is central for NET formation
22 evelopment of specific inhibitors of protein-arginine deiminase 4 (PAD4), an enzyme required for NET
23  differentiation factor 88 (MYD88), peptidyl arginine deiminase 4 (PAD4), and gasdermin D (GSDMD) for
24                                     Peptidyl arginine deiminase 4 (PAD4), which binds proteins and ci
25 wo known autocitrullination sites in Protein Arginine Deiminase 4 (PAD4, R372 and R374) and show that
26                                     Peptidyl arginine deiminase 4 (PADI4) inhibition in mice blocked
27 its target gene and binding partner peptidyl-arginine deiminase 4 (PADI4).
28  extracellular traps (NETs) through peptidyl arginine deiminase 4 (PADI4).
29                        Inhibition of protein arginine deiminase 4, an enzyme important for the releas
30 s also reduced by citrullination by peptidyl arginine deiminase 4, or digestion by serine proteases.
31 racellular trap formation involving peptidyl arginine deiminase 4.
32 ke use of histone citrullination by peptidyl arginine deiminase-4 (PADI4) in contact to particulate a
33                                PAD4 (protein-arginine deiminase-4) is a calcium-dependent enzyme that
34 ing of the nuclear DNA catalyzed by peptidyl arginine deiminase-4.
35                                              Arginine deiminase accelerates substrate hydrolysis 6 x
36 y 5.2) determined that strain 1457 devoid of arginine deiminase activity (1457 DeltaADI) was signific
37                                      Protein arginine deiminase activity depends on high intracellula
38 e and mutant Manfredo strains for the enzyme arginine deiminase (AD) showed that significant activity
39                                            L-arginine deiminase (ADI) catalyzes the hydrolysis of L-a
40                                              Arginine deiminase (ADI) catalyzes the hydrolytic conver
41                                            L-arginine deiminase (ADI) catalyzes the irreversible hydr
42                                            l-Arginine deiminase (ADI) catalyzes the irreversible hydr
43 ose was to evaluate the effects of pegylated arginine deiminase (ADI) in terms of toxicity, tumor res
44                                              Arginine deiminase (ADI) inhibits growth in various ASS-
45 is based on the use of recombinant bacterial arginine deiminase (ADI) isolated from the cells of a re
46 cA1 and arcA2) to assess the function of the arginine deiminase (ADI) pathway in organic acid resista
47 atabolism of the amino acid arginine via the arginine deiminase (ADI) pathway supplements energy prod
48 susceptible to therapeutic intervention with arginine deiminase (ADI), an enzyme responsible for cons
49  plasma arginine deprivation using pegylated arginine deiminase (ADI-PEG 20) against primary AMLs in
50                            Purpose Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino
51 e by the arginine-degrading enzyme pegylated arginine deiminase (ADI-PEG 20).
52  exploit arginine deprivation with pegylated arginine deiminase (ADI-PEG20) as a therapeutic.
53 ole of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20) has not been evaluated in
54                 The development of pegylated arginine deiminase (ADI-PEG20) has renewed interest in a
55 Arg-degrading recombinant protein, pegylated arginine deiminase (ADI-PEG20), has been in clinical tri
56 nsitive to arginine depletion with pegylated arginine deiminase (ADI-PEG20).
57                                              Arginine deiminase (ADI; EC 3.5.3.6.), an arginine-degra
58 s, including ornithine carbamoyltransferase, arginine deiminase, alpha-enolase, and alpha- and beta-g
59 ncreased transcript levels of genes encoding arginine deiminase and a putative serine dehydratase.
60                                    Arginase, arginine deiminase and arginine decarboxylase are potent
61 enter phase 2 randomized clinical trial, the Arginine Deiminase and Mesothelioma (ADAM) study, was co
62 ion in the anr gene (anaerobic regulation of arginine deiminase and nitrate reduction) that controls
63  efficacy of arginine deprivation (pegylated arginine deiminase) and chemotherapy (cisplatin), offeri
64 ivities for acetaldehyde dehydrogenase ExaC, arginine deiminase ArcA, and glyceraldehyde 3-phosphate
65  cristatus and P. gingivalis, and identified arginine deiminase (ArcA) of S. cristatus as the signali
66  (SAPP) derived from Streptococcus cristatus arginine deiminase (ArcA) was able to repress the expres
67  replacement mutants were constructed within arginine deiminase (arcA1 and arcA2) to assess the funct
68 TGases) (protein cross-linking) and peptidyl-arginine deiminase (conversion of arginines to citrullin
69                                  In peptidyl arginine deiminase-deficient mice, not forming NETs, inf
70  stability (t(1/2)=4.8h) whereas a bacterial arginine deiminase evaluated in phase II clinical trials
71 nhibitory activity correlates with levels of arginine deiminase expression in S. cristatus.
72                                            L-Arginine deiminase from Pseudomonas aeruginosa (PaADI) c
73  levels and highly upregulated expression of arginine deiminase genes were observed in the double mut
74                                     Peptidyl arginine deiminases have been shown to be hyperactive in
75 ginine in biofilm growth and the function of arginine deiminase in USA300 clones led us to geneticall
76 ue THH can be solubilized following peptidyl-arginine deiminase modification.
77  genetically inactivate the sole copy of the arginine deiminase operon by deleting the arginine/ornit
78                                     Peptidyl arginine deiminase (PAD) catalyzes the post-translationa
79                                     Peptidyl arginine deiminase (PAD) enzymes are a known modifier of
80                                      Protein arginine deiminase (PAD) enzymes catalyze the conversion
81 es into the citrulline amino acid by protein arginine deiminase (PAD) family members.
82 y foci in vivo, LL-37 is exposed to peptidyl arginine deiminase (PAD), an enzyme released by inflamma
83 tially dependent on the activity of peptidyl arginine deiminase (PAD).
84 ls undergo histone citrullination by protein arginine deiminase (PAD)4, exocytosis of chromatin and e
85                                      Protein arginine deiminases (PAD) 4 is an enzyme that catalyzes
86 ation of arginine, are generated by peptidyl arginine deiminases (PAD).
87 nation of arginine to citrulline by peptidyl arginine deiminase (PAD4), change protein structure and
88 e response proteins and bone-marrow-specific arginine deiminase PADI4.
89                                  The protein arginine deiminases (PADs) are a family of enzymes that
90                                      Protein arginine deiminases (PADs) catalyze the hydrolysis of pe
91                                      Protein arginine deiminases (PADs) catalyze the post-translation
92                                      Protein arginine deiminases (PADs) hydrolyze the side chain of a
93 are generated via the actions of the protein arginine deiminases (PADs), are known to develop in the
94 these autoantibodies are produced by protein arginine deiminases (PADs), particularly PAD4.
95 version of arginine-to-citrulline by protein arginine deiminases (PADs), whose dysregulation is impli
96 zed by a group of enzymes called the protein arginine deiminases (PADs).
97 by the levels of arginine catabolism via the arginine deiminase pathway (ADS), acidogenicity, and glo
98 nduced in ATL included those involved in the arginine deiminase pathway and a total of 140 carbohydra
99 novel mobile genetic element that encodes an arginine deiminase pathway and an oligopeptide permease
100 d decrease in the expression of genes in the arginine deiminase pathway during stringent response act
101 eration through pyruvate fermentation or the arginine deiminase pathway, and we add lineages capable
102 P from arginine catabolism by enzymes of the arginine deiminase pathway, encoded by the arcDABC opero
103  oxidative phosphorylation and ATP-providing arginine deiminase pathway.
104 nd appeared to be unrelated to ArcD from the arginine deiminase pathway.
105 luded the Padi family, encoding the peptidyl arginine deiminases responsible for citrulline protein m
106 Arginine metabolism by oral bacteria via the arginine deiminase system (ADS) increases the local pH,
107                                          The arginine deiminase system (ADS) is associated with argin
108                                          The arginine deiminase system (ADS) is responsible for the p
109                                          The arginine deiminase system (ADS) of S. gordonii enables c
110 nous ornithine produced by species using the arginine deiminase system.
111 al expression and anaerobic induction of the arginine deiminase system.
112   We show that the constitutive ACME-encoded arginine-deiminase system (Arc) allows USA300 to thrive
113 restingly, both arginine-free conditions and arginine deiminase treatment were demonstrated to kill f
114  One of the citrullinating enzymes, peptidyl arginine deiminase type 4 (PAD-4), is genetically associ
115                        Inhibition of protein-arginine deiminase type 4 (PAD4), a regulator of NETosis
116 ing NET formation via inhibition of peptidyl arginine deiminase type 4 or abrogation of reactive oxyg
117 of neutrophil elastase (NE(-/-)) or peptidyl arginine deiminase type IV (Pad4(-/-)) (enzymes that for
118    Fate-mapping studies of neonatal peptidyl arginine deiminase type IV (Padi4)-specific thymocytes r
119 -acetylgalactosaminyltransferase 3, peptidyl arginine deiminase type-2, and interleukin-15 receptor s
120 sease is up to 5.6%.) PADI3 encodes peptidyl arginine deiminase, type III (PADI3), an enzyme that pos
121 asmic droplets is first modified by peptidyl-arginine deiminase which denatures it and makes it more

 
Page Top